GlycoMimetics, Inc.
GLYC
Price:
$0.1648
Market Cap:
$10.63M
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat va...[Read more]
Industry
Biotechnology
IPO Date
2014-01-10
Stock Exchange
NASDAQ
Ticker
GLYC
The ROE as of September 2024 (TTM) for GlycoMimetics, Inc. (GLYC) is -116.81%
According to GlycoMimetics, Inc.’s latest financial reports and current stock price. The company's current ROE is -116.81%. This represents a change of 257.06% compared to the average of -32.72% of the last 4 quarters.
GlycoMimetics, Inc. (GLYC) Historical ROE (quarterly & annually)
How has GLYC ROE performed in the past?
The mean historical ROE of GlycoMimetics, Inc. over the last ten years is -66.00%. The current -116.81% ROE has changed 77.00% with respect to the historical average. Over the past ten years (40 quarters), GLYC's ROE was at its highest in in the June 2015 quarter at 18.81%. The ROE was at its lowest in in the December 2022 quarter at -68.04%.
Average
-66.00%
Median
-37.15%
Minimum
-217.40%
Maximum
-21.89%
GlycoMimetics, Inc. (GLYC) ROE by Quarter and Year
Discovering the peaks and valleys of GlycoMimetics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 185.61%
Maximum Annual ROE = -21.89%
Minimum Annual Increase = -94.00%
Minimum Annual ROE = -217.40%
| Year | ROE | Change |
|---|---|---|
| 2023 | -96.06% | -55.82% |
| 2022 | -217.40% | 180.96% |
| 2021 | -77.38% | 97.34% |
| 2020 | -39.21% | 11.73% |
| 2019 | -35.09% | 49.37% |
| 2018 | -23.50% | -15.50% |
| 2017 | -27.80% | -69.15% |
| 2016 | -90.11% | 185.61% |
| 2015 | -31.55% | 44.11% |
| 2014 | -21.89% | -94.00% |
GlycoMimetics, Inc. (GLYC) Average ROE
How has GLYC ROE performed in the past?
The current ROE of GlycoMimetics, Inc. (GLYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-130.28%
5-year avg
-93.03%
10-year avg
-66.00%
GlycoMimetics, Inc. (GLYC) ROE vs. Peers
How is GLYC’s ROE compared to its peers?
GlycoMimetics, Inc.’s ROE is less than Mineralys Therapeutics, Inc. (0%), greater than Foghorn Therapeutics Inc. (-42.61%), less than Inventiva S.A. (140.34%), less than Dyne Therapeutics, Inc. (550.46%), greater than aTyr Pharma, Inc. (-68.85%), greater than Trevi Therapeutics, Inc. (-56.83%), greater than Cue Biopharma, Inc. (-49.92%), greater than AN2 Therapeutics, Inc. (-142.93%), greater than BioAtla, Inc. (-54.72%), greater than Assembly Biosciences, Inc. (-169.69%), greater than Spero Therapeutics, Inc. (-121.55%), less than Achilles Therapeutics plc (20.70%), greater than Instil Bio, Inc. (-47.36%), greater than Neoleukin Therapeutics, Inc. (-55.57%), greater than null (-47.64%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $582.30M | |
| -42.61% | $552.73M | |
| 140.34% | $107.36M | |
| 550.46% | $3.67B | |
| -68.85% | $131.12M | |
| -56.83% | $249.72M | |
| -49.92% | $25.49M | |
| -142.93% | $31.33M | |
| -54.72% | $83.14M | |
| -169.69% | $123.29M | |
| -121.55% | $71.89M | |
| 20.70% | $42.73M | |
| -47.36% | $430.88M | |
| -55.57% | $8.20M | |
| -47.64% | $0 |
Build a custom stock screener for GlycoMimetics, Inc. (GLYC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GlycoMimetics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
GlycoMimetics, Inc. (GLYC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like GlycoMimetics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is GlycoMimetics, Inc.'s ROE?
How is the ROE calculated for GlycoMimetics, Inc. (GLYC)?
What is the highest ROE for GlycoMimetics, Inc. (GLYC)?
What is the 3-year average ROE for GlycoMimetics, Inc. (GLYC)?
What is the 5-year average ROE for GlycoMimetics, Inc. (GLYC)?
How does the current ROE for GlycoMimetics, Inc. (GLYC) compare to its historical average?